Newly Updated Treatment Guidelines

[Guest guest]

Newly Updated Treatment Guidelines

The U.S. Department of Health and Human Services (DHHS) – the federal agency

responsible for setting health-related policies in the United States – publishes

treatment guidelines for people living with HIV. Their newest guidelines were

just released.

The guidelines recommend preferred and alternative regimens for people starting

treatment for the first time. As new drugs are approved and results

of new clinical studies are announced, the guidelines on when to start treatment

and which drugs to start with are updated.

When Should I Start Treatment, and What Should I Take First?

http://www.uptilt.com/ct.html?s=4xx,5spb,3ro,dlg,qsi,2e9,fq7v

 

When Should I Change My Treatments, and Which Drugs Should I Switch To?

http://www.uptilt.com/ct.html?s=4xx,5spb,3ro,cdjv,6pno,2e9,fq7v

 

Recent Treatment News

===============================================

1) Anti-HIV agents show diverse dyslipidemia risks

http://www.uptilt.com/ct.html?s=4xx,5spb,3ro,4a04,dlqw,2e9,fq7v

In patients undergoing HIV therapy, different combinations of antiretroviral

drugs are associated with different lipid profiles, researchers report

in the March 15th issue of the Journal of Infectious Diseases. Some might

increase the risk of heart disease.

2) HIV infection boosts severe malaria risk

http://www.uptilt.com/ct.html?s=4xx,5spb,3ro,cd7s,8wiz,2e9,fq7v

3) Underlying HIV infection is associated with a two-fold higher risk of severe

malaria and a six- to eight-fold higher risk of death, according to the

results of a study conducted in South Africa.

4) Co-administration of didanosine and tenofovir brings CD4 cell counts down

http://www.uptilt.com/ct.html?s=4xx,5spb,3ro,l1wy,ca6z,2e9,fq7v

In patients infected with the human immunodeficiency virus, co-administration of

standard-dose didanosine and tenofovir reduces the CD4 count,

according to a new study.

5) HAART may reduce HHV-8 shedding in HIV-infected men

http://www.uptilt.com/ct.html?s=4xx,5spb,3ro,fir8,9d3x,2e9,fq7v

Highly active antiretroviral therapy (HAART) appears to reduce oral shedding of

human herpesvirus-8 (HHV-8) -- the virus associated with Kaposi's

sarcoma -- in HIV-infected men who have sex with men (MSM), Seattle-based

researchers report in the March 1st issue of the Journal of Acquired

Immunodeficiency Syndromes.